As of January 23, 2025, AN2 Therapeutics (ANTX) has a market cap of $37.647 million USD. According to our data, AN2 Therapeutics is ranked No.8311 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 23, 2025 | $37.65 M |
-8.70%
|
Dec 31, 2024 | $41.23 M |
-93.27%
|
Dec 29, 2023 | $0.61 B |
115.01%
|
Dec 30, 2022 | $0.28 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Vir Biotechnology
VIR
|
$1.45 B |
0.000 M
|
USA
|
Arvinas
ARVN
|
$1.25 B |
0.000 M
|
USA
|
Vertex Pharmaceuticals
VRTX
|
$110.22 B |
0.001 M
|
USA
|
Gilead Sciences
GILD
|
$115.95 B |
0.002 M
|
USA
|
Biogen
BIIB
|
$20.80 B |
0.000 M
|
USA
|
Regeneron Pharmaceuticals
REGN
|
$74.73 B |
1.236 B
|
USA
|
Moderna
MRNA
|
$14.82 B |
-0.000 M
|
USA
|
Sarepta Therapeutics
SRPT
|
$11.09 B |
0.000 M
|
USA
|
Exelixis
EXEL
|
$9.39 B |
0.000 M
|
USA
|
Incyte
INCY
|
$13.95 B |
-0.000 M
|
USA
|
Novavax
NVAX
|
$1.41 B |
-0.000 M
|
USA
|
Amgen
AMGN
|
$146.98 B |
0.004 M
|
USA
|
Alkermes
ALKS
|
$4.89 B |
-0.000 M
|
Ireland
|
Pfizer
PFE
|
$147.40 B |
-0.003 M
|
USA
|
Market Cap | = | ANTX Stock Price | * | ANTX Shares Outstanding |
= | $1.26 | * | 29.88 M | |
= | $37.65 M |